Vaccination Flashcards
live Vaccinations
MMR (Measles, Mumps, Rubella) Roto Teq Varicella, Zoster Yellow Fever Oral Typhoid & Oral Polio Flu-mix (Intranasal Influenza)
Polysaccharride Vs. Conjugated vaccines
Polysaccharride: Elderly, T cells independent, not for children younger than 2
Conjugated: T-cell depended, booster, increase immunogenicity in children younger than 2
Multi Vaccine administration
Inactivatedvaccines can be administered either simultaneously or at any time before or after live vaccines
Live vaccines not administered on the same day should be administered at least 4 weeks apart
- Oral vaccines can be given anytime
Administration intervals
Increasing the interval between doses of a multidose vaccine does not diminish the effectiveness of the vaccine
Decreasingthe interval between doses of a multidose vaccine may interfere with antibody response and protection
Vaccine doses should not be administered at intervals less than the minimum intervals or earlier than the minimum age
CI for vaccine
Live: allergy, Pregnancy, Immunosuppression
Inactive: Allergy, encephalopathy
Corticosteroid Immunosuppression
Definitions:
20 mg or more per day of prednisone x 14 days
2 mg/kg or more per day of prednisone x 14 days
NOT aerosols, alternate day, short courses, topical
Glucocorticoid Activity Equivalents:
Hydrocortisone –80mg/day or 8mg/kg/day x 14 days
Methylprednisolone –16mg/day or 1.6mg/kg/day x 14 days
Dexamethasone –3mg/day or 0.3mg/kg/day x 14 days
DTaP
children 6week to 6 yr
CI: encephalopathy within 7 days after vaccine
Tdap
No history need a series of 3 vaccination
Td at least 4 weeks after the Tdap dose
OK for pregnancy
CI: Encephalopathy within 7 days after vaccination with a pertussis- containing vaccine
Precaution: Guillain-Barre syndrome within 6 weeks
MMR CI
neomycin allergy
Influenza
6mos - 8yrs for 1st time
- 2 dose at least 4 weeks apart
inactive influenza vaccine IIV indication
Pulmonary, CV, Metabolic, renal, HIV, immunosuppression, respiratory disfunction
Pneumococcal vaccination
pure polysaccharide 23 valent
Conjugated 13 valent
ACIP Recommendations for PCV13 and PPSV23 Use
Both PCV13 and PPSV23 should be administered routinely in series to all adults aged ≥65 years (Box).
Pneumococcal vaccine-naïve persons. Adults aged ≥65 years who have not previously received pneumococcal vaccine or whose previous vaccination history is unknown should receive a dose of PCV13 first, followed by a dose of PPSV23. The dose of PPSV23 should be given 6–12 months after a dose of PCV13. If PPSV23 cannot be given during this time window, the dose of PPSV23 should be given during the next visit. The two vaccines should not be coadministered, and the minimum acceptable interval between PCV13 and PPSV23 is 8 weeks.
Previous vaccination with PPSV23. Adults aged ≥65 years who have previously received ≥1 doses of PPSV23 also should receive a dose of PCV13 if they have not yet received it. A dose of PCV13 should be given ≥1 year after receipt of the most recent PPSV23 dose. For those for whom an additional dose of PPSV23 is indicated, this subsequent PPSV23 dose should be given 6–12 months after PCV13 and ≥5 years after the most recent dose of PPSV23 (15).
Potential Time-Limited Utility of Routine PCV13 Use Among Adults ≥65 Years. The recommendations for routine PCV13 use among adults aged ≥65 years will be reevaluated in 2018 and revised as needed.
ACIP recommendations for routine use of PCV13 in adults aged ≥19 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leak, or cochlear implants remain unchanged (6).
Papillomavirus
Bivalent (Cervarix): females only 9-26 years old-Types 16 & 18 0.5mL IM 3 dose series: 0,1 to 2 months, 6 months Not recommended during pregnancy, SE: syncope
Quadravalent (Gardasil): females and males 9-26 years old-Type 6, 11, 16 & 18
Varivax
Varicella
Zostavax
Herpe zoster
